Revenue in Q3 2024 increased 20%, driven by volume growth from Mounjaro and Zepbound, partially offset by $1.42 billion of ...

The company has two rising stars that could soon boost revenue considerably. The FDA approved Kisunla as a treatment for ...

Ladies and gentlemen, thank you for standing-by, and welcome to the Lilly Q3 2024 Earnings Call. [Operator Instructions] I ...

The FDA approved Kisunla as a treatment for Alzheimer's disease in July and Ebglyss in treating atopic dermatitis in September. Both Kisunla and Ebglyss hold the potential to become blockbuster drugs.

Operator Ladies and gentlemen, thank you for standing by and welcome to the Lilly Q3 2024 earnings call. [Operator ...

The new product approvals for Ebglyss and Kisunla, exciting new pipeline data for tirzepatide, donanemab, imlunestrant and lebrikizumab, as well as key milestone achievements in our supply network ...

We achieved several key pipeline milestones this quarter, including the approval of Ebglyss in the U.S. for the treatment of moderate-to-severe atopic dermatitis. The approval of Kisunla in Japan ...

Eli Lilly's EBGLYSS, a drug for moderate-to-severe atopic dermatitis, has shown promise in improving skin conditions and reducing itchiness. Meanwhile, the company has initiated legal action ...

In other good news, in September, the Food and Drug Administration (FDA) approved Lilly's new eczema treatment, Ebglyss. In the long-term ADjoin study, treatment with the monthly injection controlled ...